Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 10/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 9/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503285 | 1.00 | ITGAL (0.46) | ITGALITGB2ICAM1CAPN1MEN1 | |
| SCHEMBL8297366 | 0.94 | ITGAL (0.51) | ITGALITGB2ICAM1CAPN1MEN1 | |
| SCHEMBL6495908 | 0.94 | ITGAL (0.51) | ITGALITGB2ICAM1CAPN1MEN1 | |
| SCHEMBL6495913 | 0.94 | ITGAL (0.51) | ITGALITGB2ICAM1CAPN1MEN1 | |
| SCHEMBL6497925 | 0.94 | ITGAL (0.45) | ITGALITGB2ICAM1CAPN1MEN1 | |
| SCHEMBL6497938 | 0.94 | ITGAL (0.45) | ITGALITGB2ICAM1CAPN1MEN1 | |
| SCHEMBL6497930 | 0.94 | ITGAL (0.45) | ITGALITGB2ICAM1CAPN1MEN1 | |
| SCHEMBL6497150 | 0.93 | ITGAL (0.48) | ITGALITGB2ICAM1CAPN1NPC1 | |
| SCHEMBL6497168 | 0.93 | ITGAL (0.48) | ITGALITGB2ICAM1CAPN1NPC1 | |
| SCHEMBL6497139 | 0.93 | ITGAL (0.48) | ITGALITGB2ICAM1CAPN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | ITGAL 1193/4885ITGB2 1979/4885ICAM1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.